BMC Musculoskelet Disord. 2025 Apr 21;26(1):381. doi: 10.1186/s12891-025-08275-x.
ABSTRACT
BACKGROUND: Osteoporosis is often responsible for bone fragility and increased fracture risk due to the micro-architectural deterioration of bone tissue. In addition to nutritional supplements, exercise is considered an adjunct factor in safeguarding bone health. This study aimed to investigate the effects of 16-week high-intensity interval training (HIIT) and vitamin D supplementation on bone mineral density (BMD) in women with osteoporosis.
TRIAL DESIGN: This study used a four-arm pretest-posttest experimental randomized controlled design.
METHODS: One hundred twenty sedentary women aged (30-50 years), diagnosed with osteoporosis were recruited in this study. Patients were randomly classified into four groups with 30 patients in each group: control group (normal daily activities), exercise group (HIIT-exercise for 16 weeks), Vitamin D group (vitamin D 800IU/ day for 16 weeks), and concurrent group (HIIT exercise plus vitamin D for 16 weeks). Anthropometric measurements, BMD, and serum levels of vitamin 25-(OH) D, Osteocalcin, s-BAP, and calcium were estimated in all participants before and after exercise training.
RESULTS: Serum samples revealed that bone resorption markers, osteocalcin, total calcium, s-BAP, and vitamin 25(OH) D significantly improved in all groups; there was greater improvement in the HIIT training-vitamin D group than in the HIIT training, vitamin D, and control groups. Furthermore, the HIIT training-vitamin D group showed improvements in hip (right and left) and lumbar spine BMD than the HIIT training, Vitamin D, and Control groups. BMD improvements correlated positively with serum osteocalcin levels and total calcium and negatively with BMI and s-BAP.
CONCLUSIONS: Sixteen weeks of HIIT and vitamin D consumption showed greater benefits for BMD levels in women with osteoporosis than either vitamin D consumption or HIIT training alone. Therefore, HIIT plus vitamin D consumption may be a strategic option to prevent BMD reduction with aging or to slow demineralization.
TRIAL REGISTRATION: The study protocol was retrospectively registered at ‘ClinicalTrials.gov PRS’ under the trial identifier NCT06624657, dated 1/10/2024.
PMID:40259289 | DOI:10.1186/s12891-025-08275-x
